Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
Completed
Conditions studied: HIV Infections, Healthy
In brief
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.
Key facts
- Study ID
- NCT00001210
- Run by
- National Cancer Institute (NCI)
- People needed
- 60
- Starts
- 1986-11-01
- Expected to finish
- 2000-09-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: any. Healthy volunteers: accepted.
Where it is running
- National Cancer Institute (NCI) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.